Carboplatin-induced gene expression changes in vitroare prognostic of survival in epithelial ovarian cancer

Panagiotis A. Konstantinopoulos(Harvard University), Dimitrios Spentzos(Beth Israel Deaconess Medical Center), Kamana Pillay(Beth Israel Deaconess Medical Center), Elena Fountzilas(European University Cyprus), Stephen A. Cannistra(Beth Israel Deaconess Medical Center), Towia A. Libermann(Beth Israel Deaconess Medical Center), Luiz F. Zerbini(University of Cape Town)
BMC Medical Genomics
November 28, 2008
10.1186/1755-8794-1-59
Cited by 60

Related Papers

Review of precision cancer medicine: Evolution of the treatment paradigm
|Cancer Treatment Reviews|2020|747
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
|Oncotarget|2016|616
Gene Expression Profile of <i>BRCA</i>ness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
|Journal of Clinical Oncology|2010|488
Clinical trial design in the era of precision medicine
|Genome Medicine|2022|279
A metabolic prosurvival role for PML in breast cancer
|Journal of Clinical Investigation|2012|272